The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).
Kohei Shitara
No relevant relationships to disclose
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Merck; Yakult
Research Funding - Bristol-Myers Squibb
Hiroyuki Uetake
No relevant relationships to disclose
Takeshi Kato
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Takeharu Yamanaka
No relevant relationships to disclose
Yasuo Ohashi
Employment or Leadership Position - Statcom
Stock Ownership - Statcom
Honoraria - Chugai Pharma; Sanofi ; Shionogi
Research Funding - Astellas Pharma; Kyowa Hakko Kirin; Takeda
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck Serono; Takeda
Research Funding - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Yakult